Funding for this research was provided by:
European and Developing Countries Clinical Trials Partnership (98595 Twice yearly treatment for the control of LF TMA 2015 CDF-979)
Received: 27 September 2017
Accepted: 6 February 2018
First Online: 13 February 2018
Ethics approval and consent to participate
: The study was carried out as part of a larger implementation research project titled “Community-based trial of annual versus biannual single-dose Ivermectin plus Albendazole against Wuchereria bancrofti infection in human and mosquito populations, which was reviewed and approved by the ethical review committee of the Ghana Health Service (GHS-ERC: 04112/2016). It was also reviewed by the NMIMR IRB (CPN 062/16–17) with Federal Wide Assurance Registration (FWA 00001824). All respondents were above 18 years of age and signed an informed consent form. Community consent was also sought for the study at community durbars.
: Not applicable
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.